{"title":"Disrupting BRD4-BD1-p62 engagement restores protective autophagy","authors":"Jifa Zhang,Yu Cao,Chengyong Wu,Yang Li,Juncheng Chen,Doudou Wang,Yao Xiao,Binghan Xue,Cailing Gan,Xin Chen,Yuxi Wang,Tinghong Ye,Liang Ouyang","doi":"10.1016/j.chembiol.2026.09.007","DOIUrl":"https://doi.org/10.1016/j.chembiol.2026.09.007","url":null,"abstract":"Impaired protective autophagy contributes to idiopathic pulmonary fibrosis (IPF), yet therapeutic strategies that restore this process remain limited. Here, we identify SKLB-39b, a BRD4-BD1-selective inhibitor that restores protective autophagy and attenuates pulmonary fibrosis. SKLB-39b exhibits over 100-fold selectivity for BRD4-BD1 relative to BRD4-BD2 and nearly 10-fold greater affinity for BRD4-BD1 than for BRD2/3-BD1. Mechanistically, we identify a BRD4-BD1-p62 interaction that links BET bromodomain function to autophagy regulation. By engaging Leu92 and Ile146 through a hydrophobic binding mode, SKLB-39b disrupts this interaction, restores ULK1-dependent autophagy, and provides a structural framework for BD1-selective inhibitor design. SKLB-39b outperformed JQ-1 in suppressing fibroblast activation, epithelial-mesenchymal transition, and collagen deposition in experimental fibrosis while showing favorable pharmacokinetic exposure and no overt toxicity in the mouse studies performed. These findings establish the BRD4-BD1-p62 interface as a druggable target for restoring protective autophagy in IPF.","PeriodicalId":265,"journal":{"name":"Cell Chemical Biology","volume":"25 1","pages":""},"PeriodicalIF":8.6,"publicationDate":"2026-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149124077","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Targeting ZDHHC15-mediated S-acylation of CD155 reactivates anti-tumor immunity","authors":"Xuanpu Zhang,Jie Zou,Jian Lin,Yu Xiao,Yue Zhu,Bokan Chen,Ziye Zhu,Yizhen Ding,Xinmei Zhou,Yinghong Yang,Xiaoyi Wang,Weijie Zhang,Min Zhang,Xia Lin,Pinglong Xu,Baoen Chen","doi":"10.1016/j.chembiol.2026.09.006","DOIUrl":"https://doi.org/10.1016/j.chembiol.2026.09.006","url":null,"abstract":"The immune checkpoint CD155 is frequently upregulated across multiple malignancies and drives tumor progression and immune evasion, yet the posttranslational mechanisms regulating its stability and activity remain unclear. Here, we identify S-acylation as a key regulator of CD155 stability and immunosuppressive function. Using chemical reporters, we demonstrate that CD155 is S-acylated at three cytoplasmic cysteines by the acyltransferase ZDHHC15 and deacylated by the thioesterases PPT1/APT1. S-acylation protects CD155 from lysosomal degradation and promotes its interaction with Sprouty2 to sustain oncogenic ERK signaling. Genetic inhibition of ZDHHC15 disrupts CD155 S-acylation, triggering CD155 degradation, enhancing CD8+ T cell infiltration, and suppressing tumor growth in syngeneic models. We further show that the FDA-approved CDK4/6 inhibitor abemaciclib promotes CD155 degradation by upregulating PPT1 and enhancing lysosome biogenesis. Our work identifies reversible CD155 S-acylation as a druggable regulatory mechanism that links protein lipidation to immune checkpoint stability and reveals an unexpected immune-potentiating mechanism of abemaciclib.","PeriodicalId":265,"journal":{"name":"Cell Chemical Biology","volume":"3 1","pages":""},"PeriodicalIF":8.6,"publicationDate":"2026-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149090229","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Rational design of protease-resistant lipopeptides for combating antibiotic-resistant bacteria.","authors":"Jiajun Wang, Haoran Xu, Yu Sun, Na Dong, Weikang Yu, Shiqi He, Anshan Shan","doi":"10.1016/j.chembiol.2026.09.001","DOIUrl":"https://doi.org/10.1016/j.chembiol.2026.09.001","url":null,"abstract":"<p><p>Given the surge in antibiotic resistance, antimicrobial peptides have emerged as promising alternatives to conventional antibiotics; however, their therapeutic potential remains hindered by proteolytic instability and insufficient potency. Herein, we integrated an anti-proteolytic Arg-Pro scaffold with N-terminal fatty acid modification to improve peptide stability and membrane-binding affinity. A series of lipopeptides was synthesized and systematically evaluated for antimicrobial efficacy, stability, and cytotoxicity, yielding C<sub>12</sub>RP7 as the lead candidate. C<sub>12</sub>RP7 exhibited potent broad-spectrum activity against 20 tested strains, including multi-drug resistant pathogens, with a high therapeutic index (TI = 64.20) and low toxicity. It also retained functional stability in the presence of physiological salts, serum, and proteases. In murine models of peritonitis and enteritis, C<sub>12</sub>RP7 treatment significantly reduced bacterial burden, attenuated systemic inflammation, restored intestinal barrier integrity, and modulated the gut microbiota. These findings support C<sub>12</sub>RP7 as a protease-resistant, potent, and biocompatible lipopeptide with potential for treating bacterial infections.</p>","PeriodicalId":265,"journal":{"name":"Cell Chemical Biology","volume":" ","pages":""},"PeriodicalIF":9.0,"publicationDate":"2026-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149101839","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Christina E. Lee,Judith Martinez,Anna Amine,Wei Zhang,Chih-Hao Lu,Xingyuan Zhang,He You,Ching-Ting Tsai,Melissa L. Nakamoto,Bianxiao Cui
{"title":"Curved adhesions resist disruption by high-affinity αv-integrin inhibitors","authors":"Christina E. Lee,Judith Martinez,Anna Amine,Wei Zhang,Chih-Hao Lu,Xingyuan Zhang,He You,Ching-Ting Tsai,Melissa L. Nakamoto,Bianxiao Cui","doi":"10.1016/j.chembiol.2026.08.017","DOIUrl":"https://doi.org/10.1016/j.chembiol.2026.08.017","url":null,"abstract":"Integrins are transmembrane adhesion receptors and major therapeutic targets in cancer and fibrotic diseases. High-affinity αv-integrin inhibitors, including cilengitide and MK-0429, were developed to block integrin-dependent cell adhesions. These inhibitors have been shown to disrupt integrin-mediated focal adhesions on flat, ligand-coated surfaces. Here, we demonstrate that these inhibitors are ineffective against curved adhesions, a class of integrin-mediated adhesion structures that assemble in response to membrane curvature. We find that, unlike focal adhesions, curved adhesions form under low mechanical tension, rendering them resistant to these inhibitors that act by blocking force transmission. As a result, these inhibitors also do not prevent cancer cell invasion into soft, fibrous three-dimensional extracellular matrices, a process that depends on curved adhesions. These findings expose a limitation of current integrin-targeting strategies and may help explain why some inhibitors have underperformed in clinical trials.","PeriodicalId":265,"journal":{"name":"Cell Chemical Biology","volume":"53 1","pages":""},"PeriodicalIF":8.6,"publicationDate":"2026-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149067374","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Cinzia Barresi,Eleonora Maino,Weiqiang Chen,Jakob J. Prömer,Alexia Bock-Pereda,Markus Hartl,Markus A. Rüegg,Ruth Herbst
{"title":"Crk/Crk-L-mediated Rapgef1 recruitment couples MuSK signaling to AChR anchoring at the neuromuscular junction","authors":"Cinzia Barresi,Eleonora Maino,Weiqiang Chen,Jakob J. Prömer,Alexia Bock-Pereda,Markus Hartl,Markus A. Rüegg,Ruth Herbst","doi":"10.1016/j.chembiol.2026.08.014","DOIUrl":"https://doi.org/10.1016/j.chembiol.2026.08.014","url":null,"abstract":"The neuromuscular junction (NMJ) is established through reciprocal signaling between motoneurons and skeletal muscle, a process critically dependent on the receptor tyrosine kinase MuSK. Although MuSK activation by Agrin, Lrp4, and Dok-7 is well characterized, the temporal organization of downstream signaling remains unclear. Here, we define the MuSK proximity proteome using TurboID-based proximity labeling combined with mass spectrometry. We identified 74 MuSK-associated proteins, including known substrates and previously unreported interactors. Among early signaling components, the adapter Crk-L emerged as a central hub linking MuSK to small GTPase pathways. We further identified Rapgef1 as a Crk-L-associated effector required for Agrin-dependent acetylcholine receptor (AChR) phosphorylation and clustering. Rapgef1 loss in adult muscle led to NMJ fragmentation. We propose that these defects result from reduced cytoskeletal anchorage of AChRs due to compromised Rapsyn/AChR interaction. These findings uncover Rapgef1 as a key regulator of MuSK-mediated signaling and highlight dynamic mechanisms governing NMJ formation and maintenance.","PeriodicalId":265,"journal":{"name":"Cell Chemical Biology","volume":"88 1","pages":""},"PeriodicalIF":8.6,"publicationDate":"2026-09-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149013603","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Signe Mathiasen,Jozsef Meszaros,Chase Webb,Peter Geggier,Wesley B. Asher,Nevin A. Lambert,Jonathan A. Javitch
{"title":"G protein diffusion states reveal receptor binding dynamics at single-molecule scale","authors":"Signe Mathiasen,Jozsef Meszaros,Chase Webb,Peter Geggier,Wesley B. Asher,Nevin A. Lambert,Jonathan A. Javitch","doi":"10.1016/j.chembiol.2026.08.013","DOIUrl":"https://doi.org/10.1016/j.chembiol.2026.08.013","url":null,"abstract":"G protein-coupled receptors (GPCRs) signal through heterotrimeric G proteins, yet the kinetics of receptor-G protein interactions in cells remain poorly understood. Using single-molecule imaging, we tracked individual Gαi1 proteins diffusing in the plasma membrane, expecting that receptor binding should slow these rapidly diffusing lipid-anchored proteins to match the substantially slower transmembrane GPCRs. Gαi1-Halo showed no detectable slowing upon dopamine D2 receptor activation. In contrast, the nucleotide-decoupled Gαi1 4A-Halo mutant exhibited receptor-dependent slowing with a lifetime of ∼0.8 s. Agonist increased the Gαi1 4A-Halo association rate without affecting the lifetime of the receptor-engaged complex, consistent with the idea that agonist efficacy is reflected in an increased probability of productive G protein engagement. These findings suggest that native GPCR-G protein interactions are not resolved at 15 ms time resolution and establish a diffusion-based approach for studying receptor-G protein kinetics in living cells.","PeriodicalId":265,"journal":{"name":"Cell Chemical Biology","volume":"30 1","pages":""},"PeriodicalIF":8.6,"publicationDate":"2026-09-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149010173","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Cell Chemical BiologyPub Date : 2026-09-17Epub Date: 2026-07-21DOI: 10.1016/j.chembiol.2026.06.010
Tianyu Ma, Tianli Luo, Ming Wang
{"title":"Dual-function PROTAC suppresses ferroptosis and restores neuronal function via brain-targeted delivery","authors":"Tianyu Ma, Tianli Luo, Ming Wang","doi":"10.1016/j.chembiol.2026.06.010","DOIUrl":"10.1016/j.chembiol.2026.06.010","url":null,"abstract":"<div><ul><li><span>•</span><span><div>Dual-function dACSL4 concurrently degrades ACSL4 and activates PPARγ signaling</div></span></li><li><span>•</span><span><div>DACSL4 suppresses ferroptosis via PUFA remodeling and PPARγ-GPX4 axis activation</div></span></li><li><span>•</span><span><div>Brain-targeted dACSL4 delivery suppresses ferroptosis and restores motor function</div></span></li></ul></div><div>Targeted protein degradation (TPD) offers a transformative approach for drug discovery, yet its application in the central nervous system (CNS) is hindered by the blood-brain barrier and the need for multi-pathway modulation in complex neurodegenerative diseases. This study introduces a dual-function PROTAC, <strong>dACSL4</strong>, which achieves synergistic ferroptosis suppression by simultaneously degrading the pro-ferroptotic enzyme ACSL4 and activating the neuroprotective PPARγ pathway. Beyond simple protein degradation, we demonstrate that precise linker optimization can leverage geometric constraints to divert the fate of PROTAC from proteolysis to functional activation, providing a modular strategy for designing “degrader-plus-agonist” bifunctional molecules. To overcome the challenges of CNS delivery, we developed ROS-responsive, biodegradable lipid nanoparticles (BAmP-TK12) for intranasal administration, enabling brain-preferred protein degradation and robust therapeutic efficacy in a Parkinson’s disease model. By designing dual-function PROTAC and brain-preferred delivery, this study provides a non-invasive strategy for regulating ferroptosis and restoring neuronal function for treating neurodegenerative disorders.</div><div><div>Targeted protein degradation (TPD) via proteolysis-targeting chimeras (PROTACs) offers a promising strategy for modulating disease-associated proteins, yet effective brain-preferred protein degradation remains challenging. Herein, we report a dual-function PROTAC, <strong>dACSL4,</strong> and its nose-to-brain delivery for brain-preferred protein degradation and therapeutic suppression of ferroptosis in neurodegeneration. <strong>dACSL4</strong> selectively degrades acyl-CoA synthetase long-chain family member 4 (ACSL4) while concurrently activating peroxisome proliferator-activated receptor γ (PPARγ), thereby coordinating lipid metabolism and oxidative stress to suppress neuronal ferroptosis. <strong>dACSL4</strong> achieved up to 30-fold greater protection against neuronal ferroptosis compared to conventional ferroptosis inhibitors. Intranasal delivery of <strong>dACSL4</strong> using biodegradable lipid nanoparticles (BAmP-TK12) enabled brain-preferred ACSL4 degradation and PPARγ activation, reducing lipid peroxidation and preserving dopaminergic neurons in a Parkinson’s disease model, ultimately improving motor function. Our findings establish a modular strategy for brain-preferred protein degradation and highlight the therapeutic potential of dual-function degraders for ferroptosis suppression in neurodegene","PeriodicalId":265,"journal":{"name":"Cell Chemical Biology","volume":"33 9","pages":"Pages 1270-1283.e8"},"PeriodicalIF":9.0,"publicationDate":"2026-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148547319","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}